Zura Bio Limited (ZURA) News
Follow Zura Bio Limited (ZURA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ZURA Reports Fiscal Q3 Loss
Profit attributable to shareholders was -7635万美元, down 42.79% year over year. Basic EPS was -0.62美元.
EQUITY | Oct 28, 2026, 05:30 AM UTC
M
Zura Bio Reports Third-Quarter Loss per Share
EQUITY | Oct 27, 2026, 11:42 AM UTC
M
Zura Bio Q3 Pretax Profit USD -27.046 Million
EQUITY | Oct 27, 2026, 11:32 AM UTC
L
Zura Bio Reports Q3 Net Income of USD -25.825 Million
EARNINGS | Oct 27, 2026, 11:31 AM UTC
M
Zura Bio Q3 Operating Income: USD -28.773 Million
EARNINGS | Oct 27, 2026, 11:31 AM UTC
M
Zura Bio Reports Third-Quarter 2026 Financial Results
Zura Bio reported financial results for the third quarter of 2026; the supplied text is truncated before any figures or further details.
EQUITY | Oct 27, 2026, 11:30 AM UTC
H
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 1% on Wednesday. Shares of BKV Corp (NYSE: BKV ) rose sharply after the company announced that a subsidiary executed into a n equipment supply contract. BKV
LIVE | Oct 07, 2026, 02:08 PM UTC
M
ZURA nears pivotal-trial readouts for IL-17/BAFF bispecific in autoimmunity
ZURA says upcoming pivotal-trial data in hidradenitis suppurativa and systemic sclerosis will test a bispecific antibody targeting IL-17 and BAFF, aiming to address efficacy ceilings in autoimmune diseases.
EQUITY | Sep 09, 2026, 02:59 PM UTC
M
ZURA advances tibulizumab dual-target bispecific in autoimmune pivotal trials
ZURA is advancing a multifunctional antibody pipeline, with tibulizumab leading pivotal trials for hidradenitis suppurativa and systemic sclerosis. The bispecific targets IL-17 and BAFF for potential superior efficacy, w
EQUITY | Sep 09, 2026, 02:07 PM UTC
L
Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio to Participate in the Cantor Global Healthcare Conference
EQUITY | Aug 31, 2026, 08:30 PM UTC
L
Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target
Wedbush analyst Martin Fan reiterates Zura Bio (NASDAQ: ZURA ) with a Outperform and maintains $15 price target.
EQUITY | Jul 01, 2026, 01:56 PM UTC